Stock Watch: Investors Reward Those Who Raise Their Guidance
But How Sustainable Are Vaccine And Diagnostic Revenues?
Executive Summary
Oncology diagnoses and therefore revenues are returning as we emerge from the pandemic, but the recovery also brings the challenges of reduced diagnostic and eventually vaccine revenues.
You may also be interested in...
Roche Battered By Biosimilars But Holds On To Initial Forecast
Roche insisted that “biosimilar competition is only one factor in the overall picture,” as it reported another set of depleted figures for its three powerhouse biologic brands: Avastin, MabThera/Rituxan and Herceptin.
Lilly/BI's Jardiance Scores A Win In Heart Failure Where Rivals Have Not
A Phase III trial in heart failure with preserved ejection fraction showed a benefit, which could result in a broad heart failure label for the SGLT2 inhibitor.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.